|
Lexaria Bioscience Corp (LEXX) |
|
Lexaria Bioscience Corp
LEXX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Lexaria Bioscience growth rates, revenue grew
in IV. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.72 %
Lexaria Bioscience net loss decreased from $-3 millions, to $-2 millions in IV. Quarter 2024,
• More on LEXX's Growth
|
|
Lexaria Bioscience realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 5.1 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 56.57.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.29.
• More on LEXX's Valuation
|
|
|
|
|
Lexaria Bioscience realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 5.1 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 56.57.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.29.
Lexaria Bioscience Price to Book Ratio is at 3.43 lower than Industry Avg. of 81.19. and higher than S&P 500 Avg. of 0.01
• More on LEXX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com